BioNTech (BNTX) Stock Forecast & Price Target

$122.68

+2.88 (+2.40%)

(As of 10/4/2024 ET)

BioNTech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
5

Buy
9

Based on 14 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 5 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$127.15
3.65% Upside

According to the 14 analysts' twelve-month price targets for BioNTech, the average price target is $127.15. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $85.00. The average price target represents a forecasted upside of 3.65% from the current price of $122.68.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

BNTX Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$127.15	$109.09	$111.70	$158.69
Forecasted Upside	3.65% Upside	21.29% Upside	38.78% Upside	42.70% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

Next opportunity for crypto millions (Ad)

October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…

Go here to discover the coin that could define this historic bull run with gains kicking off this mo

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	3.65% Upside	10,592.03% Upside	7.03% Upside
News Sentiment Rating	Positive News See Recent BNTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/24/2024	Morgan Stanley 3 of 5 stars		Upgrade	Equal Weight ➝ Overweight	$93.00 ➝ $145.00	+28.26%
9/19/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Boost Target	Buy ➝ Buy	$95.00 ➝ $150.00	+33.87%
9/18/2024	UBS Group 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$97.00 ➝ $131.00	+5.04%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$96.00 ➝ $150.00	+21.49%
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $150.00	+23.75%
9/16/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$113.00 ➝ $113.00	-8.43%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
9/16/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral	$91.00 ➝ $125.00	+1.30%
8/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$98.00 ➝ $85.00	+7.50%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/2/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Inline	$100.00	+7.85%
5/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$123.00 ➝ $122.00	+32.90%
3/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$171.00	+87.66%
2/28/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$113.00 ➝ $100.00	+8.80%
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%
3/28/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Zhiqiang Shu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$260.00	+111.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:33 AM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 3, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

BioNTech SE has been consistently investing in research and development for innovative immunotherapies, which could lead to breakthrough treatments for cancer and infectious diseases.
Recent institutional inflows from hedge funds and financial institutions indicate growing confidence in BioNTech SE's potential for future growth and profitability.
The company's strong financial position with a low debt-to-equity ratio of 0.01 and high quick and current ratios of 7.40 and 7.54 respectively, provide stability and liquidity for long-term investors.
Despite recent revenue declines, BioNTech SE's market capitalization of $29.37 billion and positive beta of 0.23 suggest resilience and potential for stock price appreciation.
Goldman Sachs Group Inc. significantly increased its position in BioNTech SE during the fourth quarter, indicating institutional confidence in the company's future prospects.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

BioNTech SE has reported negative net margins and returns on equity, indicating current profitability challenges that may impact investor returns in the short term.
The company's recent quarterly earnings report showed a significant miss on EPS estimates, reflecting potential volatility in stock performance and investor sentiment.
Analyst predictions of a negative EPS for the current fiscal year may deter risk-averse investors looking for immediate positive returns.
BioNTech SE's revenue decline of 23.3% year-over-year raises concerns about the company's ability to sustain growth and market competitiveness in the biotechnology sector.
Harding Loevner LP's substantial investment in BioNTech SE during the fourth quarter may indicate a high level of risk associated with the company's stock, potentially leading to increased market volatility.

BNTX Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $127.15, with a high forecast of $171.00 and a low forecast of $85.00.
: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 5 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BNTX shares.
: According to analysts, BioNTech's stock has a predicted upside of 3.65% based on their 12-month stock forecasts.
: Over the previous 90 days, BioNTech's stock had 6 upgrades by analysts.
: BioNTech has been rated by research analysts at Bank of America, Deutsche Bank Aktiengesellschaft, HC Wainwright, Hsbc Global Res, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, TD Cowen, and UBS Group in the past 90 days.
: Analysts like BioNTech less than other "medical" companies. The consensus rating score for BioNTech is 2.71 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Next opportunity for crypto millions (Ad)

The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine…

Go here to discover the crypto that's about to leave Wall Street in the dust.

This page (NASDAQ:BNTX) was last updated on 10/6/2024 by MarketBeat.com Staff

From Our Partners